Moderna's Trading Volume Surges 86% to $405 Million, Ranking 244th Despite Stock Price Drop
1min read On May 1, 2025, Moderna's trading volume reached $405 million, marking an 86.03% increase from the previous day and ranking 244th in the day's stock market activity. However, Moderna's stock price fell by 5.29%.
Moderna announced plans to reduce annual spending by approximately $1.5 billion by 2027 to counter slowing COVID-19 vaccine sales. The company aims to increase investment in oncology and other areas to offset the decline in revenue from its COVID-19 vaccines.
Moderna's combination flu/COVID-19 vaccine, initially expected to receive regulatory approval this year, has been delayed until 2026. The FDA has requested late-stage efficacy data, pushing back the approval timeline. This delay is part of a broader strategy by moderna to cut costs and focus on more promising areas of its pipeline.
Moderna reported a 35% decrease in total revenue for the first quarter of 2025, with net product sales falling 49% to $86 million. The company attributed this decline to the winding down of certain clinical trials and programs, as well as the timing of trial activities. Despite the revenue drop, Moderna reiterated its 2025 sales guidance and announced a cost-cutting initiative to reduce expenses significantly by 2027.
Moderna is deprioritizing the development of its combination flu/COVID-19 vaccine for younger adults, focusing instead on older adults where vaccine uptake is higher. The company aims to reduce its operating expenses by up to $1.7 billion by 2027, with R&D costs falling 19% to $856 million in the first quarter. This cost reduction is part of a broader strategy to improve efficiency and focus on more promising areas of its pipeline.
